FULCRUM THERAPEUTICS, INC. (FULC) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Current obligations | 10.30M USD | Liabilities, Current |
| Cash and equivalents | 48.47M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $10.30M | $48.47M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $9.86M | $50.26M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $13.05M | $197.53M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $11.63M | $47.08M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $8.98M | $42.59M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $8.10M | $42.18M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $11.04M | $58.21M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $14.51M | $72.63M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $12.70M | $86.70M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $10.69M | $39.95M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $13.68M | $25.56M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $14.07M | $30.08M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $14.80M | $33.97M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $14.41M | $34.73M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $16.73M | $35.10M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $14.70M | $90.94M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $22.12M | $40.15M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $18.29M | $33.31M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $19.20M | $35.41M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $20.60M | $65.47M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $22.51M | $56.78M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $22.63M | $100.75M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $26.73M | $57.05M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $26.45M | $85.22M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $13.94M | $75.72M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $14.18M | $25.38M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $12.14M | $96.71M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $8.59M | $101.60M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $6.34M | $49.63M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | $62.45M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $4.23M | $72.80M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | $82.76M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | $7.98M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |